Table 5 Clinicopathological characteristics in the IGL (intracellular GSH low) group and the IGH (intracellular GSH high) group
Variables | IGL group (n = 32) | IGH group (n = 19) | t/χ | P value |
|---|---|---|---|---|
Menopausal status | Â | Â | 0.106 | 0.745 |
 Premenopausal | 12(37.5%) | 8(42.1%) |  |  |
 Postmenopausal | 20(62.5%) | 11(57.9%) |  |  |
Age | Â | Â | 0.042 | 0.838 |
 ≥ 50 years | 21(65.6%) | 13(68.4%) |  |  |
 < 50 years | 11(34.4%) | 6(31.6%) |  |  |
Hepatitis Infection | Â | Â | 0.045 | 0.832 |
 No | 28(87.5%) | 17(89.5%) |  |  |
 Yes | 4(12.5%) | 2(10.5%) |  |  |
ALT (U/L) | 19.503 ± 2.028 | 19.667 ± 2.419 |  |  |
AST (U/L) | 24.093 ± 2.512 | 24.146 ± 2.117 |  |  |
Chemotherapy regimen | Â | Â | 1.763 | 0.779 |
 TCb | 12(37.5%) | 9(47.4%) |  |  |
 TAC | 14(43.7%) | 7(36.8%) |  |  |
 AC-T | 3(9.4%) | 2(10.5%) |  |  |
 TP | 1(3.1%) | 1(5.3%) |  |  |
 Other | 2(6.3%) | 0(0) |  |  |
Histology | Â | Â | 0.800 | 0.670 |
 Infiltrative ductal | 17(53.1%) | 12(63.1%) |  |  |
 Infiltrative lobular | 14(43.8%) | 6(31.6%) |  |  |
 Other | 1(3.1%) | 1(5.3%) |  |  |
Tumor size | Â | Â | 0.473 | 0.492 |
 ≥ 2 cm | 29(90.6%) | 16(84.2%) |  |  |
 < 2 cm | 3(9.4%) | 3(15.8%) |  |  |
Number of tumors | Â | Â | 1.019 | 0.313 |
 1 | 21(65.6%) | 15(78.9%) |  |  |
 > 1 | 11(34.4%) | 4(21.1%) |  |  |
Grade of histology | Â | Â | 0.141 | 0.932 |
 I | 10(31.3%) | 5(26.3%) |  |  |
 II | 14(43.7%) | 9(47.4%) |  |  |
 III | 8(25.0%) | 5(26.3%) |  |  |
Lymphovascular invasion | Â | Â | 0.954 | 0.329 |
 Yes | 14(43.8%) | 11(57.9%) |  |  |
 No | 18(56.3%) | 8(42.1%) |  |  |
ER/PR | Â | Â | 0.001 | 0.980 |
 Positive | 22(68.8%) | 13(68.4%) |  |  |
 Negative | 10(31.3%) | 6(31.6%) |  |  |
HER2 | Â | Â | 0.671 | 0.413 |
 Positive | 12(37.5%) | 5(26.3%) |  |  |
 Negative | 20(62.5%) | 14(73.7%) |  |  |
Ki67 | Â | Â | 0.033 | 0.856 |
 ≥ 30% | 16(50.0%) | 10(52.6%) |  |  |
 < 30% | 16(50.0%) | 9(47.4%) |  |  |
Molecular subtype | Â | Â | 0.398 | 0.820 |
 Hormone receptor positive | 21(65.6%) | 14(73.7%) |  |  |
 Triple negative | 6(18.8%) | 3(15.8%) |  |  |
 HER2 positive | 5(15.6%) | 2(10.5%) |  |  |
N stage | Â | Â | 0.925 | 0.819 |
 0 | 13(40.6%) | 6(31.6%) |  |  |
 1 | 8(25.0%) | 4(21.1%) |  |  |
 2 | 8(25.0%) | 7(36.8%) |  |  |
 3 | 3(9.4%) | 2(10.5%) |  |  |
T stage | Â | Â | 0.269 | 0.874 |
 1 | 4(12.5%) | 2(10.5%) |  |  |
 2 | 20(62.5%) | 11(57.9%) |  |  |
 3 | 8(25.0%) | 6(31.6%) |  |  |
TNM stage | Â | Â | 0.645 | 0.724 |
 1 | 1(3.1%) | 1(5.3%) |  |  |
 2 | 22(68.8%) | 11(57.9%) |  |  |
 3 | 9(28.1%) | 7(36.8%) |  |  |
Pathological response after neoadjuvant chemotherapy |  |  | 23.117 |  < 0.001 |
 pPR | 21(65.6%) | 4(21.1%) |  |  |
 pCR | 7(21.9%) | 0(0) |  |  |
 pNC | 4(12.5%) | 15(78.9%) |  |  |
Survival status | Â | Â | 4.044 | 0.044 |
 Alive | 29(90.6%) | 13(68.4%) |  |  |
 Dead | 3(9.4%) | 6(31.6%) |  |  |